基于处方药的风险评分超过二十种:一项系统综述
该系统综述检索了Ovid MEDLINE、CINAHL和Embase至2020年3月3日,纳入25项开发或更新基于处方药风险指数的研究。这些指数针对不同年龄和临床人群,最常评估死亡率、住院和医疗费用,其预测性能差异显著。
要点
- 基于处方药的风险指数超过二十种,设计、性能和应用差异显著
- 死亡率预测的C统计量范围为0.62至0.92,住院为0.59至0.72
- 医疗费用的调整R²范围为0.06至0.62
核心结论
- 已开发超过二十种基于处方药的风险指数,其设计、性能和应用存在显著差异。
研究设计与样本
- 系统综述检索Ovid MEDLINE、CINAHL和Embase从建库至2020年3月3日,纳入开发或更新基于处方药风险指数的研究。
- 由两名评价员独立筛选并提取数据源、研究人群、队列规模、结局、研究方法和性能等信息。
- PROSPERO注册号为CRD42020165498。
主要发现
- 共检索到19112篇文章,全文筛选124篇,最终纳入25篇,每篇代表一个新的或更新的基于药物的风险指数。
- 这些指数针对不同年龄组和临床人群定制,最常评估的结局包括死亡率(36%)、住院(24%)和医疗费用(24%)。
- 死亡率预测的C统计量范围为0.62至0.92,住院为0.59至0.72,医疗费用的调整R²范围为0.06至0.62。
- 25个风险指数中有7个使用了全局药物分类算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While several prescription drug-based risk indices have been developed, their design, performance, and application has not previously been synthesized. STUDY DESIGN AND SETTING: We searched Ovid MEDLINE, CINAHL and Embase from inception through March 3, 2020 and included studies that developed or updated a prescription drug-based risk index. Two reviewers independently performed screening and extracted information on data source, study population, cohort sizes, outcomes, study methodology and performance. Predictive performance was evaluated using C statistics for binary outcomes and R2 for continuous outcomes. The PROSPERO ID for this review is CRD42020165498. RESULTS: Of 19,112 articles that were retrieved, 124 were full-text screened and 25 were included, each of which represented a de novo or updated drug-based index. The indices were customized to varied age groups and clinical populations and most commonly evaluated outcomes including mortality (36%), hospitalization (24%) and healthcare costs (24%). C statistics ranged from 0.62 to 0.92 for mortality and 0.59 to 0.72 for hospitalization, while adjusted R2 for healthcare costs ranged from 0.06 to 0.62. Seven of the 25 risk indices included used global drug classification algorithms. CONCLUSIONS: More than two-dozen prescription drug-based risk indices have been developed and they differ significantly in design, performance and application.
引用
- Mehta HB, Wang L, Malagaris I, et al. More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review. J Clin Epidemiol. 2021. PMID: 33838274. doi:10.1016/j.jclinepi.2021.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。